Skip to main content
رجوع
Watch Compare

Sensei Biotherapeutics, Inc.

جودة البيانات: 83%
SNSE
Nasdaq Manufacturing Chemicals
KWD 30.70
▼ KWD 1.01 (-3.19%)
القيمة السوقية: 41.15 M
السعر
KWD 30.70
القيمة السوقية
41.15 M
نطاق اليوم
KWD 30.30 — KWD 32.30
نطاق 52 أسبوعًا
KWD 5.26 — KWD 36.76
حجم التداول
49,878
فتح KWD 31.50
متوسط 50 يوم / 200 يوم
KWD 23.33
31.61% above
متوسط 50 يوم / 200 يوم
KWD 12.67
142.35% above

Quick Summary

النقاط الرئيسية

Negative free cash flow of -20.47 M

النمو

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-83.80%
أقل من متوسط القطاع (-53.41%)
ROIC-68.96%
Net MarginN/A
Op. MarginN/A

الأمان

Debt / Equity
N/A
Current Ratio5.81
Interest Coverage-696.50

التقييم

PE (TTM)
-1.95
أقل من متوسط القطاع (-1.48)
P/B Ratio1.79
EV/EBITDAN/A
Dividend YieldN/A

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Manufacturing (1364 نظير)
المقياس السهم وسيط القطاع
P/E -2.0 -1.5
P/B 1.8 1.6
ROE % -83.8 -53.4
Net Margin % — -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -21.09 M
ROE -83.80% ROA -71.03%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -20.47 M
ROIC -68.96% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 5.81
Interest Coverage -696.50 Asset Turnover N/A
Working Capital 21.35 M Tangible Book Value 23.01 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -1.95 Forward P/E N/A
P/B Ratio 1.79 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -49.75%
Market Cap 41.15 M Enterprise Value 30.58 M
Per Share
EPS (Diluted TTM) -16.72 Revenue / Share N/A
FCF / Share -15.27 OCF / Share -15.26
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 97.08%
SBC-Adj. FCF -22.18 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -21.09 M -30.16 M -34.10 M -48.59 M -36.79 M
EPS (Diluted) -16.72 -1.20 -1.22 -1.58 —
Gross Profit — — — — —
Operating Income -22.29 M -32.61 M -37.06 M -50.19 M -37.48 M
EBITDA — — — — —
R&D Expenses — — — — —
SG&A Expenses — — — — —
D&A 122,000.0 551,000.0 571,000.0 614,000.0 685,000.0
Interest Expense 32,000.0 90,000.0 144,000.0 219,000.0 670,000.0
Income Tax 0.0 — — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 22.90 M 45.36 M 74.37 M 118.38 M 153.23 M
Total Liabilities 4.31 M 6.98 M 9.48 M 14.97 M 6.71 M
Shareholders' Equity 18.59 M 38.39 M 64.90 M 103.41 M 146.51 M
Total Debt — — — — 567,000.0
Cash & Equivalents 8.67 M 9.99 M 13.01 M 17.80 M 7.16 M
Current Assets 21.51 M 41.93 M 67.25 M 108.59 M 148.54 M
Current Liabilities 4.25 M 5.45 M 5.64 M 9.07 M 4.89 M